Table 1.
Patient demographics and disease characteristics
| All (N = 965) | Benign tumors (N = 804) | Ovarian cancer and borderline tumors (N = 161) | |
|---|---|---|---|
| Median age at diagnosis, years (range) | 48 (18–86) (n = 853a) | 45 (18–86) (n = 704a) | 59 (27–84) (n = 149a) |
| Menopausal status, n (%) | |||
| Premenopausal | 549 (56.9) | 501 (62.3) | 48 (29.8) |
| Postmenopausal | 362 (37.5) | 251 (31.2) | 111 (68.9) |
| Unknown | 54 (5.6) | 52 (6.5) | 2 (1.2) |
| Median biomarker measurements, U/mL (range) | |||
| CA125 | 18.4 (2–11,616) | 16.1 (2–6522) | 159.2 (6.1–11,616) |
| HE4 | 54.52 (13.19–5039) | 51.61 (13.19–5039) | 149.50 (28.28–4676) |
| FIGO stage, n (%) | |||
| IA | 44 (4.6) | – | 44 (27.3) |
| IB | 3 (0.3) | – | 3 (1.9) |
| IC | 12 (1.2) | – | 12 (7.5) |
| IIA | 3 (0.3) | – | 3 (1.9) |
| IIB | 2 (0.2) | – | 2 (1.2) |
| IIC | 4 (0.4) | – | 4 (2.5) |
| IIIA | 4 (0.4) | – | 4 (2.5) |
| IIIB | 7 (0.7) | – | 7 (4.3) |
| IIIC | 52 (5.4) | – | 52 (32.3) |
| IV | 30 (3.1) | – | 30 (18.6) |
| Benign tumor type, n (%) | |||
| Cystadenoma | 179 (18.5) | 179 (22.3) | – |
| Functional cyst | 165 (17.1) | 165 (20.5) | – |
| Endometriosis | 109 (11.3) | 109 (13.6) | – |
| Cystadenofibroma | 47 (4.9) | 47 (5.8) | – |
| Dermoid cyst | 44 (4.6) | 44 (5.5) | – |
| Inclusion cyst | 44 (4.6) | 44 (5.5) | – |
| Teratoma | 34 (3.5) | 34 (4.2) | – |
| Endometrioid tumor | 20 (2.1) | 20 (2.5) | – |
| Tubo-ovarian abscess | 17 (1.8) | 17 (2.1) | – |
| Fibroma | 15 (1.6) | 15 (1.9) | – |
| Benign Brenner tumor | 5 (0.5) | 5 (0.6) | – |
| Other | 124 (12.8) | 125 (15.2) | – |
FIGO Fédération Internationale de Gynécologie et d’Obstétrique, HE4 Human epididymis protein 4
aPatients aged < 18 years were not included